^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zaltrap (ziv-aflibercept IV)

    i
    Other names: AVE0005 IV, VEGF Trap IV
    Company:
    Regeneron, Sanofi
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor, VEGF-B inhibitor
    Related drugs:
    2ms
    Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma (clinicaltrials.gov)
    P2, N=3, Terminated, Sidney Kimmel Cancer Center at Thomas Jefferson University | Completed --> Terminated; Slow accrual
    Trial termination
    |
    Zaltrap (ziv-aflibercept IV)
    1year
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CD8 (cluster of differentiation 8) • HGF (Hepatocyte growth factor) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • FGF (Fibroblast Growth Factor) • MLANA (Melan-A)
    |
    Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)
    over1year
    Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Oct 2023 --> Feb 2024
    Trial initiation date • Metastases
    |
    Libtayo (cemiplimab-rwlc) • Zaltrap (ziv-aflibercept IV)
    almost2years
    Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. (PubMed, Cancer Med)
    The combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.
    P1 data • Journal • Combination therapy • Metastases
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    almost2years
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    almost2years
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    almost2years
    A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection (clinicaltrials.gov)
    P=N/A, N=140, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)
    almost2years
    Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. (PubMed, Cancer Immunol Immunother)
    Although limited by sample size and follow-up, these findings highlight the potential of the combination of ziv-aflibercept antiangiogenic therapy with pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment and the need for further research to improve outcomes in anti-PD-1-resistant melanoma.
    Journal • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)
    almost2years
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    CD8 (cluster of differentiation 8) • HGF (Hepatocyte growth factor) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule) • FGF (Fibroblast Growth Factor) • MLANA (Melan-A)
    |
    Keytruda (pembrolizumab) • Zaltrap (ziv-aflibercept IV)
    2years
    Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (clinicaltrials.gov)
    P1/2, N=134, Recruiting, Neonc Technologies, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Zaltrap (ziv-aflibercept IV)
    2years
    Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial • Metastases
    |
    Libtayo (cemiplimab-rwlc) • Zaltrap (ziv-aflibercept IV)
    2years
    TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (clinicaltrials.gov)
    P3, N=202, Active, not recruiting, GCS IHFB Cognacq-Jay | Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: Oct 2022 --> Jun 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    KDR (Kinase insert domain receptor) • FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C)
    |
    5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)